GFP Reporter Cell Line - C666-1

The C666-1 cell line is a highly specialized human nasopharyngeal carcinoma (NPC) model, originally derived from an undifferentiated NPC tumor. Growing as an adherent epithelial monolayer, this line is uniquely distinguished in oncological research as one of the extremely rare in vitro NPC models that stably retains the Epstein-Barr virus (EBV) genome during long-term continuous culture. The GFP Reporter Cell Line - C666-1 enhances this foundational virology and oncology model through stable lentiviral transduction, engineering the cells to constitutively express green fluorescent protein (GFP). This targeted genetic integration ensures that the modified cells continuously emit a robust, bright green fluorescent signal when exposed to the appropriate excitation light. Crucially, this stable modification transforms the standard line into a highly sensitive visual tracking tool while strictly preserving its original aggressive malignant phenotype, baseline cellular morphology, and, most importantly, its native EBV-positive status.

Leveraging its rare retention of the EBV genome, this reporter cell line is a critical resource for pre-clinical research focused on EBV-driven head and neck malignancies. In vitro, the constitutive green fluorescence facilitates advanced live-cell imaging, spatial tracking, and high-throughput flow cytometry assays. Researchers rely on this robust optical readout to continuously monitor cellular morphology, evaluate cell proliferation, and rapidly screen the direct cytotoxic effects of novel chemotherapeutics, epigenetic modulators, and anti-viral therapies without requiring complex secondary staining procedures. In vivo, the GFP-expressing cells are heavily utilized to establish reliable xenograft mouse models for nasopharyngeal carcinoma. The persistent fluorescent signal allows scientists to conduct highly precise ex vivo histological analyses, enabling the high-resolution mapping of primary tumor margins and the early detection of micro-metastases in surrounding tissues or lymph nodes. This targeted spatial tracking significantly accelerates the development of precision interventions and immunotherapies specifically designed to combat EBV-associated carcinomas.